Fig. 1From: Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trialStudy flow diagram showing all patients screened for inclusion in the study and reasons for ineligibilityBack to article page